AS Bravo Pharmaceuticals — Financial statements & reports

Name: Datreal.com Company Registry
Creator: Datreal.com
License: https://opendatacommons.org/licenses/by/1.0/

Income statement

Income statement
Year	Revenue	Inventory changes	Long-term investment expenses	Other operating income (by nature)	Material expenses	Labour expenses	Depreciation	Cost of goods sold	Gross profit	Selling expenses	Administrative expenses	Other operating income (by function)	Other operating expenses	Profit from equity investments	Other long-term investment income	Interest income	Investment revaluation	Interest expenses	Extraordinary income	Extraordinary expenses	Profit before taxes	Income tax provisions	Profit after taxes	Other taxes	Extraordinary dividends	Net profit
2026	0 €	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2025	0 €	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Year	Assets					Assets					Liabilities				Equity		Total liabilities & equity
Year	Cash	Securities	Receivables	Inventories	Total current assets	Investments	Intangible assets	Fixed assets	Total non-current assets	Total assets	Future housing repairs	Current liabilities	Non-current liabilities	Provisions	Capital	Total equity	Total liabilities & equity
2026	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2025	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Year	Operating cash flow	Investing cash flow	Financing cash flow	Net cash change
2026	Not available
2025	Not available

Year	Total taxes	Change	Social tax	Employees
2026	3042 €	75.4%	2826 €	2+100%
2025	12 355 €	49.2%	10 208 €	10%
2024	24 334 €	3.3%	18 231 €	10%
2023	23 557 €	8.4%	18 610 €	10%
2022	21 725 €	-	18 336 €	1